Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis

NCT00665639 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT00665639
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00665639 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Comparative Trial of Two Dosing Regimens of Micafungin (FK463) Versus Caspofungin for the Treatment of Esophageal Candidiasis
Lead sponsor
Astellas Pharma Inc
Phase
Phase 3
Overall status
Completed
Start date
June 30, 2004
Completion date
December 31, 2004
Enrollment
454 (actual)
Sites
31

Conditions

As the registry lists them; a condition with its own page is linked.

candidiasis, oral